Es wird kein Kindle Gerät benötigt. Laden Sie eine der kostenlosen Kindle Apps herunter und beginnen Sie, Kindle-Bücher auf Ihrem Smartphone, Tablet und Computer zu lesen.

  • Apple
  • Android
  • Windows Phone
  • Android

Geben Sie Ihre Mobiltelefonnummer ein, um die kostenfreie App zu beziehen.

Kindle-Preis: EUR 13,32
inkl. MwSt.

Diese Aktionen werden auf diesen Artikel angewendet:

Einige Angebote können miteinander kombiniert werden, andere nicht. Für mehr Details lesen Sie bitte die Nutzungsbedingungen der jeweiligen Promotion.

An Ihren Kindle oder ein anderes Gerät senden

An Ihren Kindle oder ein anderes Gerät senden

Facebook Twitter Pinterest <Einbetten>
The Cure in the Code: How 20th Century Law is Undermining 21st Century Medicine von [Huber, Peter W.]
Anzeige für Kindle-App

The Cure in the Code: How 20th Century Law is Undermining 21st Century Medicine Kindle Edition


Alle Formate und Ausgaben anzeigen Andere Formate und Ausgaben ausblenden
Preis
Neu ab Gebraucht ab
Kindle Edition
"Bitte wiederholen"
EUR 13,32

Kindle Storyteller 2016: Der Deutsche Self Publishing Award
Kindle Storyteller 2016: Der Deutsche Self Publishing Award
Von 15. Juni bis 15. September Buch hochladen und tollen Preis gewinnen Jetzt entdecken

Produktbeschreibungen

Pressestimmen

“[An] urgent, compelling account of how 21st-century medicine is being hampered by a regulatory regime built for the science of the 20th century.”
Wall Street Journal

“[An] exciting and authoritative review of accelerating advances in personalized medicine.”
Barron’s

“Spotlighting an area where federal laws and regulations lag far behind technological innovation, the author, a Manhattan Institute senior fellow, maintains that medicine’s rapidly developing capacity to decode individual human genomes and tailor patients’ treatments accordingly – as with breast cancer – is being hindered by...‘outdated drug-approval protocols developed decades ago during medicine’s long battle with the infectious epidemics of the past.’”
Pittsburgh Tribune-Review

“[Huber is] one of the few men walking the Earth who could write a book about FDA reform that is not only profitable but pleasurable to read. The book is exciting, in that it suggests possibilities for significant improvements in our ability to treat terrifying diseases in the near future; but it is also depressing, because its sophisticated analysis – in flying so far above regulation-deregulation and government-market binaries that dominate so many of our policy debates – cannot help but draw one’s attention to the intellectual poverty of Washington’s practically pre-Copernican approach to important policy decisions.... The book is sprinkled liberally with sentences that are thought-provoking gems, each worthy of an essay of its own.... [A] very rich book.”
National Review

“Our ability to read the genetic code heralds a transformation of modern medicine. Yet many potential medical miracles remain throttled….[Huber’s] ardor for invigorating pharmaceutical progress is apparent on every page.”
Booklist

“Intriguing.”
Kirkus Reviews

“A provocative, optimistic look at modern medicine… Huber’s challenge is sure to spark controversy as the U.S. adapts to the Affordable Care Act.”
Publishers Weekly

“A must read for physicians, patients, biotech investors, and healthcare politicians, The Cure in the Code is the most important policy book of the decade, and it could only have been written by Peter Huber, a polymathic master of both the deadly menace and huge promise of bioscience, and scathing critic of the blindness of healthcare bureaucracy.”
George Gilder, author of Knowledge and Power: The Information Theory of Capitalism

“A thoughtful and compelling account of how the federal government’s current regulatory science is not only outdated, but risks hampering scientific efforts to combat diseases at the molecular level. Marshaling insights from medicine, law, and economics, Huber makes an urgent case for how to improve the drug and therapy regulatory system to better equip physicians with innovative treatments that meet critical patient needs.”
Tom Coburn, M.D., United States Senator from Oklahoma

“Peter Huber is one of only a handful of public intellectuals with a deep understanding of science, economics, and the law. In The Cure in the Code, Huber explains scientific advances in molecular biology and genetic engineering, the economics of pharmaceuticals and medicine, and the intersection of all of these with FDA law and policy. This is a key guide to the promise of personalized medicine—personalized down to the genetic level—and also to the policies that can deliver that promise.”
Alex Tabarrok, Professor and Bartley J. Madden Chair in Economics, George Mason University

“Peter Huber has eloquently portrayed the transition of medicine from art to science in the 21st century. But The Cure in the Code offers much more as he illuminates the changes that must occur in the research, regulatory, reimbursement ecosystem if the promise of cures is to be fulfilled.”
Andrew von Eschenbach, Commissioner of the U.S. Food and Drug Administration (2005-2009)

Kurzbeschreibung


Never before have two revolutions with so much potential to save and prolong human life occurred simultaneously. The converging, synergistic power of the biochemical and digital revolutions now allows us to read every letter of life’s code, create precisely targeted drugs to control it, and tailor their use to individual patients. Cancer, diabetes, Alzheimer’s and countless other killers can be vanquished—if we make full use of the tools of modern drug design and allow doctors the use of modern data gathering and analytical tools when prescribing drugs to their patients.

But Washington stands in the way, clinging to outdated drug-approval protocols developed decades ago during medicine’s long battle with the infectious epidemics of the past. Peter Huber, an expert in science, technology, and public policy, demonstrates why Washington’s one-size-fits-all drug policies can’t deal with diseases rooted in the complex molecular diversity of human bodies. Washington is ill-equipped to handle the torrents of data that now propel the advance of molecular medicine and is reluctant to embrace the statistical methods of the digital age that can. Obsolete economic policies, often rationalized as cost-saving measures, stifle innovation and suppress investment in the medicine that can provide the best cures at the lowest cost.

In the 1980s, an AIDS diagnosis was a death sentence, until the FDA loosened its throttling grip and began streamlining and accelerating approval of life-saving drugs. The Cure in the Code shows patients, doctors, investors, and policy makers what we must now do to capture the full life-saving and cost-saving potential of the revolution in molecular medicine. America has to choose. At stake for America is the power to lead the world in mastering the most free, fecund, competitive, dynamic, and intelligent natural resource on the planet—the molecular code that spawns human life and controls our health.

Produktinformation

  • Format: Kindle Edition
  • Dateigröße: 1992 KB
  • Seitenzahl der Print-Ausgabe: 306 Seiten
  • Verlag: Basic Books; Auflage: 1 (12. November 2013)
  • Verkauf durch: Amazon Media EU S.à r.l.
  • Sprache: Englisch
  • ISBN-10: 0465069819
  • ISBN-13: 978-0465069811
  • ASIN: B00C4GRUNI
  • Text-to-Speech (Vorlesemodus): Aktiviert
  • X-Ray:
  • Word Wise: Aktiviert
  • Verbesserter Schriftsatz: Aktiviert
  • Durchschnittliche Kundenbewertung: Schreiben Sie die erste Bewertung
  • Amazon Bestseller-Rang: #1.349.071 Bezahlt in Kindle-Shop (Siehe Top 100 Bezahlt in Kindle-Shop)

  •  Ist der Verkauf dieses Produkts für Sie nicht akzeptabel?

Kundenrezensionen

Es gibt noch keine Kundenrezensionen auf Amazon.de
5 Sterne
4 Sterne
3 Sterne
2 Sterne
1 Stern

Die hilfreichsten Kundenrezensionen auf Amazon.com (beta)

Amazon.com: 4.4 von 5 Sternen 10 Rezensionen
22 von 23 Kunden fanden die folgende Rezension hilfreich
5.0 von 5 Sternen life and death 2. November 2013
Von John Thorne - Veröffentlicht auf Amazon.com
Format: Gebundene Ausgabe Verifizierter Kauf
This is a well-written and important book on the future of medicine and regulation of medicine. Don't confuse it with the debates on the Affordable Care Act; it's about the regulatory impediments to investment in and approval of new medicines. Like Huber's earlier books, this one has lots of interesting stories (some funny, many tragic) to make the broader points concrete and memorable. The opening chapter is as tightly written and compelling as Dawkins's Selfish Gene.
8 von 8 Kunden fanden die folgende Rezension hilfreich
5.0 von 5 Sternen When I Got To Be 64 Today ... I Started Thinking About Being 104 27. Dezember 2013
Von George E. Jones - Veröffentlicht auf Amazon.com
Format: Gebundene Ausgabe
The Cure in the Code book is exciting in the new paradigm of what mankind can now start to think about in a serious way .... partial Victory Over Mortality.

It's about Mr. Huber's scholarly take on HealthSpan via molecular medicine break throughs applied in personalized and individualized ways to the parts of our DNA which regulate the Aging Process and our HealthSpan.

The biggest impediment to improving our HealthSpan is the U.S. Government and in particular the bureaucratic early 1900 mindset at the FDA.

If President Obama wanted to make a seismic change there he should appoint some like Peter Huber to head the FDA,

Watch this video then buy this book. [...]
5 von 5 Kunden fanden die folgende Rezension hilfreich
5.0 von 5 Sternen A must read for every U.S. citizen. Clear, concise and riveting synthesis of our current health care dilemma 14. Februar 2014
Von Lynn M. Babington - Veröffentlicht auf Amazon.com
Format: Gebundene Ausgabe Verifizierter Kauf
The author provides a succinct and easily understood synthesis of recent breakthroughs in scientific technologies and capabilities to illustrate the unprecedented opportunity we now have to reduce human suffering and dramatically improve health of humans worldwide. He then summarizes current U.S. legislation that guides the FDA regulatory process for development of novel therapeutics, articulates how the regulations were appropriate when originally written, and then makes a compelling argument to illustrate how the current regulations are actually impeding progress. More important and more impressive - he provides thoughtful and provocative solutions to facilitate and accelerate progress.

A must read for everyone in the health care industry, especially anyone interested in how to facilitate development of novel therapeutics for currently untreatable diseases.

Actually, this is a must read for every U.S. citizen as it is only through reform of our outdated regulatory laws that the potential of modern scientific understanding can be unleashed and fully realized.
5 von 5 Kunden fanden die folgende Rezension hilfreich
5.0 von 5 Sternen excellent book 25. Februar 2014
Von Alan Winters - Veröffentlicht auf Amazon.com
Format: Gebundene Ausgabe Verifizierter Kauf
The biology is really interesting and clearly presented. The politics is shocking. Good read. I'm glad I'm too old to be affected by all this future stuff.
3 von 4 Kunden fanden die folgende Rezension hilfreich
5.0 von 5 Sternen How the FDA is impeding medical progress 9. Februar 2014
Von William B. Grant - Veröffentlicht auf Amazon.com
Format: Gebundene Ausgabe
This book goes into great detail about how the FDA is applying rules for pharmaceutical drug approval that are designed for blockbuster drugs and, as a result, block development of drugs useful for a small portion of the population, due to either being a rare disease or being linked to genetic factors. One of the main problems with drug approval is the requirement of the double-blind, randomized clinical trial. Such trials are very expensive, have to enroll many people, and cannot consider genetic variations among enrollees. As a result, the rate of drug discovery has slowed considerably. However, it is becoming increasingly apparent that genetic variations affect how people respond to drugs and even vitamins and foods. For drugs that might be useful for those with particular genetic variations related to particular diseases (called molecular medicine), people should be carefully selected. This the FDA does not permit.

The President's Council of Advisors on Science and Technology (PCAST) urged in 2012 that the FDA make "full use" of accelerated approval "for all drugs meeting ... an unmet medical need for a serious or life threatening illness." However, the FDA is moving in the opposite direction.

This book discusses many problems with the FDA process and makes suggestions on how to change it.

For more information on the problems with the FDA, see this 57 minute documentary by Gary Null:
[...]
Waren diese Rezensionen hilfreich? Wir wollen von Ihnen hören.
click to open popover